Poster
T-DXd
ESMO 2025 | October 17-21, 2025
Gastric Cancer
Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) plus paclitaxel (PTX) in second-line (2L) treatment of patients (pts) with HER2+ unresectable/metastatic gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Additional data from DESTINY-Gastric04
Filippo Pietrantonio
Oral
T-DXd
ESMO 2025 | October 17-21, 2025
Breast Cancer
Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T‑DM1) in patients with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05
Charles E. Geyer Jr.
Poster
T-DXd
ESMO 2025 | October 17-21, 2025
Tumor-agnostic
Trastuzumab deruxtecan for pretreated patients with HER2-expressing solid tumors: DESTINY-PanTumor02 part 1 final analysis
Vicky Makker
Poster
T-DXd
ESMO 2025 | October 17-21, 2025
Gastric Cancer
Trastuzumab deruxtecan in patients with HER2+ gastric cancer or gastroesophageal junction adenocarcinoma who received prior anti-HER2 treatment other than / in addition to trastuzumab in DESTINY-Gastric06
Zhi Peng
Poster
T-DXd
ESMO 2025 | October 17-21, 2025
Tumor-agnostic
Trastuzumab deruxtecan in pretreated patients with HER2-expressing solid tumors: Exploratory biomarker analysis of DESTINY-PanTumor02 part 1
Jung-Yun Lee
Mini-Oral
I-DXd
ESMO 2025 | October 17-21, 2025
Lung Cancer
Updated results from a phase 1/2 study of gocatamig for small cell lung cancer and other neuroendocrine cancers
Himisha Beltran
Pages: 1  2  3